Politics Jan 13 Tom Price, Trump’s HHS nominee, got a sweetheart deal from a foreign biotech firm When Australian biotech firm Innate Immunotherapeutics needed to raise money last summer, it offered a sweetheart deal to “sophisticated U.S. investors.” One of them was Rep. Tom Price.